semaglutide aging A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Mechanism fits the clinic --

Some specialized medical diets like those used to treat certain metabolic disorders, including phenylketonuria, homocystinuria, and maple syrup urine disease, need to be supplemented with selenium to ensure optimal selenium status in patients (51)

A.BoadaL

doi: 10.1016/J.AJOG.2024.08.024 88 GrahamDLMadkourHSNobleBLSchatschneiderCStanwoodGD

Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin

The STEP 1 trial showed that participants receiving 2.4 mg weekly for 68 weeks lost an average of 14.9% of their body weight compared to 2.4% in the placebo group